FindTrial
Sign In

Stellate ganglion block combined with ozonated autohemotherapy in the treatment of sudden hearing loss

Stellate ganglion block combined with ozonated autohemotherapy in the treatment of sudden hearing loss

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066113
Enrollment
Unknown
Registered
2022-11-24
Start date
2022-11-25
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sudden hearing loss

Interventions

experimental group:Ultrasound-guided stellate ganglion block combined with ozonated autohemotherapy with drug therapy
control group:drug therapy

Sponsors

the First Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=18 years old; 2. The first, unilateral onset of sudden deafness; 3. The course of disease <1 month, without any invasive nerve block treatment; 4. The pure sound hearing test met the diagnostic criteria of the 2015 Sudden Deaf Diagnosis and Treatment Guidelines.

Exclusion criteria

Exclusion criteria: 1. Infection at the puncture site or systemic infection; 2. Severe coagulation abnormalities; 3. History of neck surgery; 4. Central nerve or peripheral neuropathy; 5. Those who cannot cooperate to complete the project follow-up.

Design outcomes

Primary

MeasureTime frame
The average hearing threshold ;—

Secondary

MeasureTime frame
Hearing improvement;Tinnitus recovery;—

Countries

China

Contacts

Public ContactXiaokai Zhou

the First Affiliated Hospital of Nanjing Medical University

orthoxiaokaizhou@163.com+86 13770527630

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026